Welcome to our dedicated page for Cadrenal Therape news (Ticker: CVKD), a resource for investors and traders seeking the latest updates and insights on Cadrenal Therape stock.
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) is a biopharmaceutical company developing anticoagulant therapies for rare and high-risk patient populations, and its news flow reflects this specialized focus. The CVKD news page on Stock Titan aggregates company announcements, sponsored coverage, and regulatory updates related to its clinical-stage pipeline.
Readers can expect news centered on Cadrenal’s three main assets: VLX-1005, a first-in-class 12-LOX inhibitor in Phase 2 development for heparin-induced thrombocytopenia (HIT); tecarfarin, an oral vitamin K antagonist for chronic use in patients with kidney dysfunction or left ventricular assist devices; and frunexian, a parenteral Factor XIa antagonist positioned for acute hospital settings. Company communications often highlight regulatory designations such as Orphan Drug and Fast Track status, clinical trial progress, and portfolio-expanding transactions.
News items also cover corporate developments, including participation in healthcare investor conferences, partnering outreach, and board-level appointments. Financial updates, such as quarterly results and capital-raising activities disclosed via press releases and Form 8-K filings, provide additional context on how Cadrenal is funding and prioritizing its development programs.
For investors, clinicians, and researchers following the evolution of anticoagulation therapies, the CVKD news feed offers a consolidated view of Cadrenal’s milestones across chronic, acute, and immune-mediated indications. Bookmark this page to review new press releases, sponsored analytical pieces, and SEC-related announcements as they are released, and to track how the company’s strategy and pipeline advance over time.
Cadrenal Therapeutics (CVKD) has announced its participation in the inaugural Centri Capital Conference, scheduled to take place at Nasdaq in New York City on April 22, 2025. Chairman and CEO Quang X. Pham will deliver a company presentation and provide updates on tecarfarin, the company's lead asset.
Tecarfarin, a Phase 3-ready oral vitamin K antagonist anticoagulant, is being developed to address unmet needs in anticoagulation therapy. The conference will bring together capital markets representatives and investment community members, focusing on companies innovating in healthcare and life sciences sectors.
Cadrenal Therapeutics (NASDAQ: CVKD) has announced its participation in several key medical and business development conferences during Q2 2025. The company, which is developing tecarfarin, a Phase 3-ready oral vitamin K antagonist anticoagulant, will be represented at:
- 18th National Conference on Anticoagulation Therapy in Washington, D.C. (April 3-5)
- 13th annual CMO Summit 360° ® (April 7-8)
- BIO International Convention in Boston, MA (June 16-19)
Chief Operating Officer Jeff Cole and Chief Medical Officer Dr. James Ferguson will attend these events to engage with industry experts, key opinion leaders, and potential partners to advance tecarfarin development and build their specialized cardiovascular therapeutics pipeline.
Cadrenal Therapeutics (NASDAQ: CVKD) reported its full year 2024 results and updates on tecarfarin development. The company secured a collaboration with Abbott for the TECH-LVAD Phase 3 trial and received additional FDA guidance through a Type D meeting.
Key financial highlights include:
- Net loss of $10.7M in 2024 vs $8.4M in 2023
- R&D expenses of $4.2M vs $4.1M in 2023
- G&A expenses increased to $6.8M from $3.5M
- Cash position of $10.0M as of December 31, 2024
- Raised $9.8M through ATM facility ($5.1M) and warrant exercises ($4.7M)
Notable achievements include FDA Orphan Drug Designation for tecarfarin in mechanical circulatory support devices, appointment of new executive leadership, and completion of manufacturing readiness for Phase 3 trial materials.
Cadrenal Therapeutics (CVKD) has announced a significant collaboration agreement with Abbott (ABT) to support their pivotal TECH-LVAD trial, evaluating tecarfarin in patients with Left Ventricular Assist Devices (LVADs).
The collaboration focuses on testing tecarfarin, a new oral Vitamin K antagonist (VKA), with Abbott's HeartMate 3™ LVAD, which is currently the only advanced mechanical circulatory support device available in the United States for patients with advanced heart failure.
Under the agreement, Abbott will provide support in:
- Trial design
- Site identification
- Trial awareness
- HeartMate 3™ expertise
The LVAD market, valued at $1.1 billion in 2023, is projected to reach $2.4 billion by 2032, according to Business Research Insights.
Cadrenal Therapeutics (CVKD) has appointed James J. Ferguson, MD, FACC, FAHA as its new Chief Medical Officer, replacing Douglas W. Losordo, MD. Dr. Ferguson, with over 25 years of cardiovascular leadership experience, will lead the late-stage clinical development of tecarfarin, a new Vitamin K antagonist, focusing on pivotal trials in LVAD patients and other rare cardiovascular conditions requiring life-long anticoagulation therapy.
Dr. Ferguson joins from Matinas BioPharma, where he served as Chief Medical Officer. His previous roles include Head of U.S. Cardiovascular Medical Affairs at Amgen and various senior positions at AstraZeneca. The appointment aims to advance tecarfarin's development as the first innovation in vitamin K-targeted anticoagulation in 70 years.
Cadrenal Therapeutics (Nasdaq: CVKD), a late-stage biopharmaceutical company, will deliver a presentation at the 2025 BIO CEO & Investor Conference at The New York Marriott Marquis on February 10-11, 2025. CEO Quang X. Pham will present on February 10 at 4:30 pm EST in the Royale Room, providing company updates and details about their lead product tecarfarin.
The presentation will focus on tecarfarin, a novel Vitamin K antagonist (VKA) being developed as a safer anticoagulant alternative to warfarin for patients with implanted cardiac devices. Mr. Pham will be available for one-on-one meetings through the BIO partnering portal during the conference.
Cadrenal Therapeutics (Nasdaq: CVKD) has announced its participation in the upcoming Lytham Partners 2025 Investor Healthcare Summit, scheduled for January 13, 2025. The company's Chairman and CEO, Quang X. Pham, will engage in a virtual fireside chat at 10:30 a.m. Eastern time.
Cadrenal Therapeutics specializes in developing tecarfarin, a novel oral vitamin K antagonist (VKA) currently in advanced clinical development. This therapeutic is designed to provide a superior and safer anticoagulation alternative for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions.
The virtual event will be accessible through the conference website, with replay options available. Interested investors can request one-on-one meetings through Lytham Partners representatives.
Cadrenal Therapeutics (CVKD) provided its 2024 year-end update, highlighting progress in developing tecarfarin for left ventricular assist device (LVAD) patients and rare cardiovascular conditions. Key achievements include: FDA Orphan Drug Designation for tecarfarin in LVAD patients, successful fundraising of $9.8 million bringing cash balance to $11.3 million, and completion of manufacturing readiness for the upcoming Phase 3 trial.
The company held a Type B meeting with the FDA regarding the pivotal Phase 3 trial protocol, with updates expected in Q1 2025. Tecarfarin aims to provide a superior alternative to warfarin for chronic anticoagulation in LVAD patients. The company also joined the Anticoagulation Forum and was named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook.
Cadrenal Therapeutics (CVKD) announces its participation in three key events during the 43rd Annual J.P. Morgan Healthcare Conference Week in January 2025. The company will present updates on tecarfarin, their novel oral vitamin K antagonist designed for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions.
CEO Quang X. Pham will participate in the Longwood Healthcare Leaders discussions on January 11-12, attend the Nasdaq Opening Bell Ceremony on January 13, and along with COO Jeff Cole, will conduct one-on-one investor meetings during the conference. The company plans to outline its Phase 3 clinical development plan, regulatory approval strategy, and three-year vision.